Covid-19 Rapid IgM/IgG Combined Antibody Assay Pre-Screening Kit Package Insert

Model Number: K460216D

For the qualitative assessment of new coronavirus (2019-nCOV) IgG/IgM in human serum/plasma/whole blood.

INTENDED USE

The **Covid-19 Rapid IgM/IgG Combined Antibody Assay Pre-Screening Kit** is a rapid chromatographic immunoassay for the qualitative detection of IgG &IgM antibody of WUHAN New Coronavirus in human whole blood, serum, or plasma as an aid in the diagnosis of 2019-nCOV infections.

SUMMARY

Coronavirus (CoV) belongs to the genus Nestovirus, Coronaviridae and is divided into three genera: α, β, and γ. The genus α and β are only pathogenic to mammals. The genus γ mainly causes bird infections CoV is mainly transmitted through direct contact with secretions or through aerosols and droplets. There is also evidence that it can be transmitted through the fecal-oral route.

So far, there are 7 types of human coronavirus (HCoV) that cause human respiratory diseases: HCoV-229E,HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1, MERS-Co and new coronaviruses (2019) , Is an important pathogen of human respiratory infections. Among them, the new coronavirus (2019) was discovered due to Wuhan virus pneumonia cases in 2019. The clinical manifestations are systemic symptoms such as fever and fatigue accompanied by dry cough and dyspnea, etc., which can rapidly develop into severe pneumonia, respiratory failure, and acute breathing. Distress syndrome, septic shock, multiple organ failure, severe acid-base metabolism disorders, etc. are even life-threatening.

PRINCIPLE

This kit uses immunochromatography. The test card contains:1) colloidal gold-labeled recombinant new coronavirus antigen and quality control antibody gold markers;2) two detection lines (G and M lines) and one quality Control line (C line) of nitrocellulose membrane. The M line is immobilized with a monoclonal anti-human IgM antibody for detecting a new coronavirus IgM antibody; the G line is immobilized with a reagent for detecting a new coronavirus IgG antibody; and the C line is immobilized with a quality control antibody.

When an appropriate amount of the test sample is added to the sample hole of the test card, the sample will move forward along the test card under the action of the capillary. If the sample contains an IgM antibody, the antibody will bind to the colloidal gold-labeled new coronavirus antigen. The immune complex will be captured by the anti-human IgM antibody immobilized on the membrane to form a purple-red M line showing that the new coronavirus IgM antibody is positive.

If the sample contains an IgG antibody, the antibody will bind to the colloidal gold-labeled new coronavirus antigen and the immune complex will be captured by the reagent immobilized on the membrane to form a purple-red G line, indicating that the new coronavirus IgG antibody is positive.

If the test lines G and M are not colored a negative result is displayed. The test card also contains a quality control line C. The fuchsia quality control line C should appear regardless of whether a test line appears. The quality control line is a color band of the quality control antibody immune complex. If the quality control line C does not appear, the test result is invalid, and the sample needs to be tested again with another test card.

REAGENTS

The test contains 2019-nCOV virus envelope protein particles and anti-human IgG anti-human IgM antibody conjugated gold particles coated on the membrane.

PRECAUTIONS

1. For professional in vitro diagnostic use only. Do not use the kit beyond the expiration date.
2. Do not eat, drink or smoke in the area where the specimens or kits are handled.
3. Do not use the test if the pouch is damaged.
4. Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout testing and follow the standard procedures for proper disposal of specimens.
5. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are being tested.
6. The used test should be discarded according to local regulations.

STORAGE AND STABILITY

1. The original packaging should be stored at 4~ 30℃to avoid light, keep dry.
2. The test device is stable through the expiration date printed on the sealed pouch. The test device must remain in the sealed pouch until use.**DO NOT FREEZE.**
3. Do not use beyond the expiration date, especially at temperatures above 30℃ or under high humidity conditions, should be used immediately once it is opened.

SPECIMEN COLLECTION AND PREPARATION

1. The 2019-nCOV IgG/IgM Rapid Test Device is intended for use with human whole blood, serum or plasma specimens only.
2. Only clear, non-hemolyzed specimens are recommended for use with this test. Serum or plasma should be separated as soon as possible to avoid hemolysis.
3. Perform testing immediately after specimen collection. Do not leave specimens at room temperature for prolonged periods. Serum and plasma specimens may be stored at 2-8°C for up to 3 days. For long term storage, serum or plasma specimens should be kept below -20°C. Whole blood collected by venipuncture should be stored at 2-8°C if the test is to be run within 2 days after collection. Do not freeze whole blood specimens. Whole blood collected by fingerstick should be tested immediately.
4. Containers containing anticoagulants such as EDTA, citrate, or heparin should be used for whole blood storage.
5. Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Avoid repeated freezing and thawing of specimens.
6. If specimens are to be shipped, pack them in compliance with all applicable regulations for transportation of etiological agents.
7. Icteric, lipemic, hemolyzed, heat treated and contaminated sera may cause erroneous results.

MATERIALS

Materials provided

Test Devices	Buffer
Disposable plastic pipette	Package insert
Lancets (for finger stick whole blood only)	Alcohol pad

Materials required but not provided

Specimen collection containers	Centrifuge (for plasma only)
Micropipette	Timer

DIRECTIONS FOR USE

Allow the test device, specimen, buffer, and/or controls to reach room temperature (15-30°C) prior to testing.

1. Bring the pouch to room temperature before opening Remove the test device from the sealed pouch and use it as soon as possible.
2. Place the test device on a clean and level surface.

For **Serum or Plasma Specimens:**

Using the **provided 5μL disposable pipette and transfer 1 drop of serum/plasma** to the specimen well of the test device then **add 1 drop of buffer** and start the timer

For **Whole Blood (Venipuncture/Fingerstick) Specimens:**

Using the **provided 5μL disposable pipette**, and **transfer 2 drops of whole blood (approximately 20μL)** to the specimen well of the test device then **add 1 drop of buffer** and start the timer.

Note: Specimens can also be applied using a micropipette.

3. Wait for the colored line(s) to appear. **Read results at 10 to 15 minutes. Do not interpret the result after 15 minutes.**

INTERPRETATION OF RESULTS

IgG POSITIVE: *The colored line in the control line region (C) appears and a colored line appears in test line region IgG. The result is positive for 2019-nCOV-IgG antibodies.

IgM POSITIVE: *The colored line in the control line region (C) appears and a colored line appears in test line region IgM.

IgG AND IgM POSITIVE: *The colored line in the control line region (C) appears and two colored lines should appear in test line regions IgG and IgM. The color intensities of the lines do not have to match. The result is positive for IgG & IgM antibodies.

*NOTE: The intensity of the color in the test line region(s) IgG and/or IgM will vary depending on the concentration of 2019-nCOV antibodies in the specimen. Therefore, any shade of color i n the test line region(s) IgG and/or IgM should be considered positive.

NEGATIVE: The colored line in the control line region (C) appears. No line appears in test line regions IgG or IgM.

I NVALID: There is no line appear in the c region.

Insufficient buffer volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the procedure with a new test device. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

QUALITY CONTROL

Internal procedural controls are included in the test. A color line appearing in the control region (C) is an internal positive procedural control It confirms sufficient specimen volume and correct procedural technique.

Control standards are not supplied with this kit however it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

LIMITATION OF USE

1. The accuracy of the test depends on the sample collection process. Improper sample collection, improper storage of samples, unfresh samples, or repeated freeze-thaw cycles of samples will affect the test results.
2. The test cassette only provides qualitative detection of the COVID-19 antibody in the sample. If you need to detect the specific content of an indicator, please use the relevant professional instruments.
3. The test result of this kit is for clinical reference only and should not be used as the sole basis for clinical diagnosis and treatment. The clinical management of patients should be considered in combination with their symptoms/signs, medical history, other laboratory tests, and treatment responses.
4. It is recommended to review the suspicious negative results by using nucleic acid detection or virus culture identification methods.
5. Analysis of the possibility of false negative results：

① Unreasonable sample collection, transportation and processing may lead to false negative results.

② Genetic variations of virus can cause changes in antibody determinants, which can lead to false negative results.

③ The optimal sample type and sampling time after infection have not been verified, so collecting samples at different times on the same patient may avoid false negative results.

[FDA]

- **This test has not been reviewed by the FDA.**
- **Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.**
- **Results from antibody testing should not be used as the sole basis to diag-nose or exclude SARS-CoV-2 infection or to inform infection status.**
- **Positive results may be due to past or present infection with non-SARS-CoV-2 corona virus strains, such as corona virus HKU1, NL63, OC43, or 229E.**
- **Not for the screening of donated blood**

SYMBOLS

Symbol	Meaning	Symbol	Meaning
IVD	In vitro diagnostic medical device		Storage temperature limit
	Manufacturer	EC REP	Authorized representative in the European Community
	Date of Manufacture		Use by date
	Do not reuse		Consult instruction foe use
LOT	Batch code	CE	Meet the requirements of EC Directive 98/79/EC
REF	Catalogue number	Σ	The number of test

Spring Healthcare Services AG
Obstgartenstrasse 5, Affoltern am Albis
CH-8910 Switzerland

EC REP

CE

Number: 1101311601
Version: 1.0
Effective Date: 2020-04-05